Immunotherapy
Bersanelli, Melissa.
Introduction
On 11 March, the WHO formally declared the corona virus disease-19 (COVID-19) outbreak a pandemic [1]. After the first cluster of cases emerged from Wuhan, in China, at the end of 2019, up today almost 287000 cases of infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been diagnosed across all five continents in the last few months
Keywords
anti-CTLA-4, anti-PD-1, anti-PD-L1, cancer patients, COVID-19, immune checkpoint inhibitors, immunotherapy, SARS-CoV-2, tocilizumab, viral infection